Roche Holding (1RO) Fair Value & Analysis
Healthcare · IT · Market cap €301B
Fair value as of: Jul 3, 2026
From 24 valuation models · updated today
Share price +8.8% over the past month.
Price vs Fair Value (12 months)
12‑month range €263.67 – €401.32 · fair‑value band €186.81 – €399.89 · the €377.80 price screens above the €280.03 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Roche Holding (1RO) currently trades at €377.80, while our model-based Fair Value estimate is €280.03 — implying the stock looks roughly 25.9% overvalued today. We read business quality at 71/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Roche Holding generated revenue of €63.4B at a net margin of 20.3%. Revenue declined 0.4% year over year. It earns a return on equity of 37.3%. Net debt stands at €26.1B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Roche Holding reported revenue of €63.4B in FY2025 versus €65.8B in FY2022, a compound −1.3%/yr. Reported net income was €12.9B in FY2025, compounding +1.2%/yr from FY2022.
Is 1RO fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,131 | $447.74 | -60% |
| Johnson & Johnson, JNJ | 4,128 MXN | 159.68 MXN | -96% |
| AbbVie Inc ABBV | $224.95 | $129.90 | -42% |
| Merck & Co MRCK34 | R$77.92 | R$40.37 | -48% |
| AstraZeneca PLC A1ZN34 | R$150.60 | R$23.54 | -84% |
| Novartis AG N1VS34 | R$77.00 | R$70.07 | -9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Roche Holding (1RO) undervalued?
What is the fair value of 1RO?
What is the quality score of 1RO?
What is the revenue of Roche Holding (1RO)?
What is the net profit margin of 1RO?
Does Roche Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.